Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nguyet Nguyen

Physician Assistant, Medical Midlothian, TX Physician Assistant

NPI 1083143093 CMS profile 10506591

4440 E Highway 287, Midlothian, TX 76065

Open in the dashboard

General payments

$15,937

659 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nguyet Nguyen of Midlothian, TX is reported in the CMS Open Payments database as having received $15,937 across 659 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,183 172
2024 General $3,828 161
2023 General $3,488 147
2022 General $2,326 101
2021 General $2,111 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nguyet Nguyen
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Nguyet Nguyen were reported at $4,183. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Nguyet Nguyen Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,111 $156 $41–$563 $132
2022 $2,326 $185 $55–$649 $149
2023 $3,488 $199 $58–$717 $160
2024 $3,828 $206 $62–$740 $164
2025 $4,183 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,825 60 payments
  2. AbbVie, Inc. $1,564 45 payments
  3. Galderma Laboratories, L.P. $1,253 49 payments
  4. Genzyme Corporation $1,132 43 payments
  5. LEO Pharma Inc. $1,061 36 payments
  6. Janssen Biotech, Inc. $784 12 payments
  7. Lilly USA, LLC $741 26 payments
  8. UCB, Inc. $734 33 payments
  9. Mayne Pharma Inc. $713 61 payments
  10. Regeneron Healthcare Solutions, Inc. $678 35 payments
  11. Other $5,452 259 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,252 649 payments
  2. Education $685 10 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,927 63 payments
  2. Otezla $1,825 60 payments
  3. ADBRY $833 30 payments
  4. TREMFYA $753 10 payments
  5. RINVOQ $740 23 payments
  6. NUZYRA $648 37 payments
  7. SKYRIZI $555 11 payments
  8. DUPIXENT Inflammation And Immunology $537 27 payments
  9. Bimzelx $527 26 payments
  10. SOTYKTU $514 37 payments
  11. Other $8,174 368 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

469

Median for Physician Assistant: 241

Drug cost

$11,762

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 104 $3,952
Doxycycline Hyclate Generic 85 $1,825
Fluorouracil Generic 19 $1,447
Tacrolimus Generic 13 $1,445
Ketoconazole Generic 59 $1,233
Metronidazole Generic 12 $577
Clindamycin Phosphate Generic 23 $378
Mupirocin Generic 45 $364
Triamcinolone Acetonide Generic 47 $234
Spironolactone Generic 12 $155

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$78,520

Of which drugs: $7,429

Medicare patients

171

Average age 71

Services billed

6,900

99 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 30%
Ischemic heart disease 25%
Chronic kidney disease 24%
Depression 22%
Cancer 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 11 5,600 $7,424

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$568 — —
ADBRY
$372 — —
SKYRIZI
$352 — —
Otezla
$273 — —
Cabtreo
$200 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

659 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record